LOS ANGELES–()–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA) investors concerning the Company’s possible violations of the federal securities laws.

If you suffered a loss on your Ginkgo investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/ginkgo-bioworks-holdings-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On October 6, 2021, Scorpion Capital published a 175-page research report alleging that Ginkgo Bioworks is a “colossal scam” and that its business model is a “shell game.” According to the report, Ginkgo Bioworks is highly dependent on related party transaction revenues and the Company is a “Frankenstein mash-up of the worst frauds of the last 20 years.”

On this news, the Company’s share price fell as much as 17% during intraday trading on October 6, 2021, thereby injuring investors.

Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice: Persons with non-public information regarding Ginkgo should consider their options to aid the investigation or take…

Read more…